NasdaqGM:ATAIPharmaceuticals
How Does Atai (ATAI)’s New EMP-01 Patent Shape Its Psychedelic Therapy Moat?
Earlier in December 2025, Atai Life Sciences N.V. received a new U.S. patent for EMP-01, its oral R-MDMA formulation being developed for social anxiety disorder and other mental health indications, providing exclusivity through 2043.
This long-dated patent protection strengthens Atai’s intellectual property position around EMP-01 just as an exploratory Phase 2a trial is enrolling, with topline results expected in the first quarter of 2026.
We’ll now examine how this extended patent...